Mobile

A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003158-12

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to compare the OS of pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 every 3 weeks to the OS of single-agent cisplatin 75 mg/m2 every 3 weeks in patients with HNC that is recurrent and not amenable to local therapy (surgery or radiation) or newly diagnosed distant metastatic disease.

Critère d'inclusion

  • Recurrent or Metastatic Head and Neck Cancer

Liens